Axa S.A. Sells 20,836 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Axa S.A. cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,430 shares of the biopharmaceutical company’s stock after selling 20,836 shares during the period. Axa S.A. owned about 0.06% of Regeneron Pharmaceuticals worth $32,776,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of REGN. State Street Corp grew its stake in Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after purchasing an additional 42,343 shares during the period. Dodge & Cox boosted its holdings in shares of Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after buying an additional 1,502,198 shares during the last quarter. Franklin Resources Inc. grew its position in Regeneron Pharmaceuticals by 1.6% during the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after buying an additional 36,821 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after buying an additional 89,579 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its position in Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after acquiring an additional 305,089 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Canaccord Genuity Group increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Truist Financial began coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $798.00 price objective for the company. UBS Group boosted their target price on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Morgan Stanley downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $767.00 price target for the company. in a research note on Wednesday, December 3rd. Finally, Jefferies Financial Group lifted their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $777.36.

Regeneron Pharmaceuticals Trading Down 1.5%

Shares of Regeneron Pharmaceuticals stock opened at $692.58 on Wednesday. The company’s 50-day moving average price is $656.15 and its 200-day moving average price is $589.72. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $791.49. The company has a market cap of $72.79 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.01 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the company earned $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.